

Positron Emission Tomography and Improved Survival in Patients With Lung Cancer

The Will Rogers Phenomenon Revisited

Karen G. Chee, MD; Danh V. Nguyen, PhD; Monica Brown, PhD;
David R. Gandara, MD; Ted Wun, MD; Primo N. Lara Jr, MD

Background: The Will Rogers phenomenon occurs when newer technology allows for more sensitive detection of tumor spread, resulting in stage migration and an apparent improvement in patient survival. We investigated whether use of highly sensitive positron emission tomography (PET) scanning in non-small cell lung cancer has had this effect.

Methods: We performed a retrospective analysis involving 12 395 patients with non-small cell lung cancer in the pre-PET (1994-1998) and PET (1999-2004) periods. Interperiod differences in staging procedures, clinical variables, and patient survival were evaluated.

Results: There was a 5.4% decline in the number of patients with stage III disease and an 8.4% increase in the

number of patients with stage IV disease in the PET period, corresponding with an increase in PET use from 6.3% to 20.1% ($P < .001$). The PET period predicted better survival with a hazard ratio (HR) of 0.95 (95% confidence interval [CI], 0.91-0.99) ($P = .02$). Use of PET was independently associated with better survival in patients with stage III (HR, 0.77; 95% CI, 0.69-0.85) and stage IV (HR, 0.64; 95% CI, 0.58-0.70) disease, but not those with stage I or II disease.

Conclusion: These data support the notion that stage migration is responsible at least in part for an apparent improvement in survival for patients with stage III and IV non-small cell lung cancer in the PET scan era.

Arch Intern Med. 2008;168(14):1541-1549

Author Affiliations: UC Davis Cancer Center (Drs Chee, Gandara, Wun, and Lara) and UC Davis Clinical and Translational Science Center (Drs Nguyen and Wun), UC Davis Health System, Sacramento, California; Veterans Administration Northern California Health Care System (Drs Gandara, Wun, and Lara), Sacramento; and the Cancer Surveillance Program, California Cancer Registry, Sacramento (Dr Brown); and Division of Biostatistics, Department of Public Health Sciences, University of California, Davis (Dr Nguyen).

STAGE MIGRATION IN ONCOLOGY describes a change in cancer stage distribution caused by advancements in technology that allow for more sensitive detection of tumor spread and can result in an apparent improvement in patient survival. Stage migration is one form of what is widely referred to as the Will Rogers phenomenon, which occurs if moving an element from one set to another raises the average values of both sets. Rogers' original quip—"When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states"—humorously illustrates this phenomenon.

In a seminal report, patients with lung cancer treated in 1977 appeared to have higher survival rates compared with those treated between 1953 and 1964, apparently as a result of stage migration from the use of newer diagnostic imaging procedures.¹ When patients were classified according to symptom stages that would be unaltered by new diagnostic procedures, the 2 cohorts had similar survival rates.

In the latter part of the 20th century, fluorodeoxyglucose F 18-positron emission tomography (FDG-PET) emerged as a stan-

dard diagnostic imaging modality for the staging of lung cancer, offering enhanced sensitivity in detecting otherwise occult tumor spread.^{2,3} Since its approval for reimbursement for lung cancer staging by Medicare in 1998, PET scanning has seen a tremendous expansion in its use and is now widely available in many communities.⁴

We hypothesized that FDG-PET scan usage in non-small cell lung cancer (NSCLC) staging is associated with a shift in stage distribution, particularly from stage III to IV, and that this shift would be characterized by an apparent improvement in survival in stage III and IV cohorts. We explored this hypothesis in a large NSCLC cohort from the Sacramento region of the population-based California Cancer Registry (CCR).

METHODS

For the purposes of this analysis, the 10-year study period from 1994 to 2004 was divided into 2: 1994 to 1998 and 1999 to 2004, henceforth known as the pre-PET and PET periods, respectively. The year 1999 was selected as the beginning of the PET period because the inflection point for increasing PET use in the da-




Figure 1. Trends in positron emission tomography (PET) scan use and non-small cell lung cancer stage, 1994 to 2004.

tabase began in 1999 (**Figure 1**) and the fact that PET was paid for by Medicare, which began a year earlier, had become more widely known in 1999.

Data were obtained from the CCR, a statewide population-based cancer surveillance system composed of 8 regional registries collecting cancer incidence and mortality information since 1988. Cases are reported to the Cancer Surveillance Section of the California Department of Public Health from hospitals and any other facilities providing care or therapy to patients with cancer residing in California.⁵ Cases included in these analyses were invasive NSCLC diagnosed between January 1, 1994, and December 31, 2004, and reported to the Sacramento Region, or Region 3, of the CCR as of October 2006. We defined NSCLC using *International Classification of Diseases for Oncology*, second and third editions, site codes C34.0-C34.9 and histology codes 8004, 8010, 8012, 8013, 8020-8022, 8031-8033, 8046, 8070-8076, 8082-8084, 8123, 8140, 8145, 8230, 8249-8253, 8255, 8260, 8310, 8430, 8550, 8560, 8574, and 8720.^{6,7}

Race/ethnicity, based on information obtained from medical records, was derived from patient self-identification, assumptions based on appearance, or inferences based on the race/ethnicity of the patient's parents, birthplace, surname, or maiden name. Hispanic ethnicity was based on information from the medical record and computerized comparisons to the 1980 US Census list of Hispanic surnames. Patients identified as Hispanic on their medical record as well as patients identified as white, black, or of unknown race but who had a Hispanic surname were classified as Hispanic. Patients for whom race/ethnicity, age, or sex were unknown were excluded from the analyses.

Socioeconomic status and rural/urban designation were assigned at the 2000 US Census block group level and based on address at the time of initial diagnosis as reported in the medical record. Quintile of socioeconomic status was derived from a principle component analysis using data from the 2000 US Census.⁸ Rural/urban designation was defined by Rural-Urban Commuting Area codes developed and categorized by the University of Washington Rural Health Research Center.

Stage at diagnosis was collected from the patient's medical record and coded according to the *AJCC Cancer Staging Manual*, 6th edition.⁹ Text fields pertaining to radiographs, scoping pro-

cedures, and any additional remarks were extracted from the CCR data management system. Chest radiograph, computed tomographic scan, magnetic resonance imaging, PET scan, mediastinoscopy, bronchoscopy, thoracoscopy, and radiofrequency ablation were coded as "done" or "not done" based on the presence or lack of keywords or phrases within the extracted text fields. Cases that could not be assigned values based on keyword coding were manually reviewed. This study was reviewed and approved by the institutional review boards at the University of California, Davis, and the CCR.

Differences in the distribution of computed tomographic and PET scan usage, age at diagnosis, sex, race, disease stage, treatment received (surgery, radiation, or chemotherapy), and Rural-Urban Commuting Area (urban vs rural) were evaluated using the *t* test for continuous variables and χ^2 testing for proportions. Survival curves were estimated using the Kaplan-Meier method¹⁰ for the pre-PET and PET periods. The log-rank statistic was used for the comparison of overall survival distributions.¹¹

Cox regression analysis¹² was used to obtain hazard ratios (HRs) for death for PET periods and use of PET, adjusted for age, sex, race, urban vs rural residence, and treatment received (surgery, radiation, or chemotherapy), allowing for different hazards for each stage. Departure from the proportional hazard assumption was checked using graphical methods based on Schoenfeld residuals vs time and testing procedure-based inclusion of time-dependent covariates. Only radiation and chemotherapy showed departure from the Cox model assumption. Thus, we considered an extended Cox model that allows for different hazards by radiation and chemotherapy (stratified Cox model). However, the conclusions and the estimates of HRs (model coefficients) did not change to a significant degree. For this reason, we have chosen to present the simpler model. Logistic regression analysis was used to evaluate the odds ratio of stage IV (relative to stage III) for the pre-PET vs PET periods adjusted for potential confounders. The Hosmer-Lemeshow goodness-of-fit test and diagnostic plots were used to assess model fit and were found to be adequate. Analyses were performed using SAS statistical software, version 9.1 (SAS Inc, Cary, North Carolina), and the statistical software R (<http://www.r-project.org/>). All *P* values are for 2-sided tests.

To assess for potential confounders and improve balance in the covariates between patients who underwent PET (PET-yes group or cases) and those who did not (PET-no group or controls), matched pairs were obtained to evaluate survival differences for each stage by matching with the propensity score (PS).^{13,14} The PS is the probability of receiving a PET scan given the covariates and was obtained for each stage based on logistic regression. Matched pairs (PET-yes and PET-no groups) within each stage were then obtained by matching cases to controls on the PS using a "greedy match" technique.¹⁵ Survival for the PET-yes and PET-no groups was estimated using the Kaplan-Meier method. After matching, covariate balance between the PET-yes and PET-no groups was compared using paired *t* test for continuous covariates and the McNemar test for categorical covariates. For covariates that were not balanced after matching on PS, Kaplan-Meier analysis was based on further stratification of those covariates (eg, chemotherapy). In addition, we also considered covariate/confounder adjustment by including the PS, together with covariates that could not be balanced, in a survival analysis using the Cox regression model.

In the data analysis, 334 patients (2.7%) were excluded because of missing follow-up time. This extremely small number would likely have negligible effects, if any, on the subsequent conclusion. Although there is growing use of multiple imputation methods for missing predictors/covariates, the theory on imputing survival time is lacking, and we chose not to impute missing follow-up time for this analysis.

Table 1. Patient Characteristics by PET Period^a

Characteristic	Pre-PET Period (1994-1998)	PET Period (1999-2004)	P Value
Age, mean (range), y	67.4 (22-98)	68.2 (21-100)	...
Male sex	2769 (56.0)	4031 (54.1)	.03
Race			
White, non-Hispanic	4149 (84.0)	6068 (81.4)]. <.001
Other	792 (16.0)	1386 (18.6)	
Residence ^b			
Urban	4273 (86.6)	6466 (86.8)]. .84
Rural	660 (13.4)	988 (13.2)	
Disease stage			
I	1094 (22.1)	1507 (20.2)]. <.001
II	239 (4.8)	279 (3.7)	
III	1694 (34.3)	2151 (28.9)	
IV	1914 (38.7)	3517 (47.2)	
Surgical treatment			
None or unknown ^c	3500 (70.8)	5533 (74.2)]. <.001
Pneumonectomy	1271 (25.7)	1713 (23.0)	
Lobectomy or partial pneumonectomy	164 (3.3)	157 (2.1)	
Lung procedure, not otherwise specified	6 (0.1)	51 (0.7)	
Radiation use			
No	2609 (52.8)	4541 (60.9)]. <.001
Yes	2332 (47.2)	2913 (39.1)	
Chemotherapy use			
No	3557 (72.0)	4669 (62.6)]. <.001
Yes	1384 (28.0)	2785 (37.4)	
CT use			
No	729 (14.8)	900 (12.1)]. <.001
Yes	4212 (85.2)	6554 (87.9)	
PET use			
No	4631 (93.7)	5956 (79.9)]. <.001
Yes	310 (6.3)	1498 (20.1)	
MRI use			
No	4720 (95.5)	7108 (95.4)]. .66
Yes	221 (4.5)	346 (4.6)	
Bronchoscopy use			
No	2664 (53.9)	4847 (65.0)]. <.001
Yes	2277 (46.1)	2607 (35.0)	
Mediastinoscopy use			
No	4768 (96.5)	7227 (97.0)]. .16
Yes	173 (3.5)	227 (3.0)	
Thoracoscopy use			
No	4897 (99.1)	7430 (99.7)]. <.001
Yes	44 (0.9)	24 (0.3)	

Abbreviations: CT, computed tomography; ellipses, not applicable; MRI, magnetic resonance imaging; PET, positron emission tomography.

^aData are given as number (percentage) of patients unless otherwise indicated.

^bIn 8 cases, no residence designation was available.

^cIncludes 6 patients who underwent unknown surgical procedures.

In survival analysis, power is related to the number of events (here, lung cancer deaths) and not the number of subjects. Because the follow-up period in our study was reasonably long for lung cancer, the event was observed for 86.9% of subjects (ie, 10 771 deaths). In regression modeling, studies suggest that at least 10 events per covariate are needed, and for our data there were more than 600 events per covariate. Therefore, the Cox model has sufficient power. For the Kaplan-Meier analysis, we did not do an a priori power analysis (ie, prestudy power).

Table 2. Patient Characteristics by PET Use^a

Characteristic	PET-No	PET-Yes	P Value
Age, mean (range), y	67.8 (23-100)	68.2 (21-93)	...
Male sex	5876 (55.5)	924 (51.1)	<.001
Race			
White, non-Hispanic	8700 (82.2)	1517 (83.9)]. .07
Other	1887 (17.8)	291 (16.1)	
Residence ^b			
Urban	9155 (86.5)	1584 (87.6)]. .22
Rural	1424 (13.5)	224 (12.4)	
Disease stage			
I	2022 (19.1)	579 (32.0)]. <.001
II	381 (3.6)	137 (7.6)	
III	3327 (31.4)	518 (28.7)	
IV	4857 (45.9)	574 (31.7)	
Surgical treatment			
None or unknown ^c	8051 (76.1)	982 (54.3)]. <.001
Pneumonectomy	251 (2.4)	70 (3.9)	
Lobectomy or partial pneumonectomy	2254 (21.3)	730 (40.4)	
Lung procedure, not otherwise specified	31 (0.3)	26 (1.4)	
Radiation use			
No	6098 (57.6)	1052 (58.2)]. .64
Yes	4489 (42.4)	756 (41.8)	
Chemotherapy use			
No	7140 (67.4)	1086 (60.1)]. <.001
Yes	3447 (32.6)	722 (39.9)	
CT use			
No	1451 (13.7)	178 (9.8)]. <.001
Yes	9136 (86.3)	1630 (90.2)	
MRI use			
No	10 067 (95.1)	1761 (97.4)]. <.001
Yes	520 (4.9)	47 (2.6)	
Bronchoscopy use			
No	6364 (60.1)	1147 (63.4)]. .007
Yes	4223 (39.9)	661 (36.6)	
Mediastinoscopy use			
No	10 284 (97.1)	1711 (94.6)]. <.001
Yes	303 (2.9)	97 (5.4)	
Thoracoscopy use			
No	10 525 (99.4)	1802 (99.7)]. .18
Yes	62 (0.6)	6 (0.3)	

Abbreviations: CT, computed tomography; ellipses, not applicable; MRI, magnetic resonance imaging; PET, positron emission tomography; PET-No, did not undergo PET; PET-Yes, underwent PET.

^aData are given as number (percentage) of patients unless otherwise indicated.

^bIn 8 cases, no residence designation was available.

^cIncludes 6 patients who underwent unknown surgical procedures.

RESULTS

PATIENT CHARACTERISTICS

A total of 13 762 patients with NSCLC were identified from the registry. Of these, 12 395 patients had adequate staging information (I through IV); this cohort made up the study population. The last date of follow-up was January 8, 2007, and the median duration of follow-up was 6.4 years. The median duration of follow-up was 4.4 years in the PET period and 4.0 years among patients who received PET. **Table 1** summarizes patient characteristics as well as treatment and imaging procedures used for disease staging, stratified by the pre-PET and PET periods. Analogous characteristics stratified by PET use are provided in **Table 2**.




Figure 2. Kaplan-Meier survival curves in the pre-positron emission tomography (PET) and PET periods (1994-1998 vs 1999-2004) for patients with stage I (A), stage II (B), stage III (C), and stage IV non-small cell lung cancer (D).

STAGE III AND IV DISEASE BY PET PERIOD

Changes in the percentages of patients with stage I through IV disease from 1994 to 2004 are depicted in Figure 1. Use of PET scans increased during this period. The increase in the percentage of patients with stage IV disease during this period coincided with a decrease in the percentage of patients with stage III disease. Overall, there was a 5.4% decline in stage III disease and an 8.4% increase in stage IV disease from the pre-PET to the PET period. There was no substantial change in the percentage of patients with stage I or II disease (Table 1). In addition, PET imaging use significantly increased from the pre-PET period to the PET period (6.5% vs 20.1%, respectively) ($P < .001$).

Logistic regression analysis was used to evaluate the odds of stage IV (relative to stage III) disease, adjusted for potential confounders (age, sex, race, disease stage, urban residence, and treatment with surgery, radiation, and chemotherapy). For the PET period, the odds ratio for stage IV

disease compared with stage III disease was 1.53 (95% CI, 1.40-1.70; $P < .001$). Thus, the adjusted odds for a diagnosis of stage IV disease was significantly higher during the PET period compared with the pre-PET period.

SURVIVAL BY DISEASE STAGE AND PET PERIOD

Unadjusted Analysis

Overall survival significantly improved during the PET period compared with the pre-PET period for stage III ($P < .001$) and IV ($P < .001$) disease. In contrast, survival for patients with stage I and II disease was unchanged. **Figure 2** shows the Kaplan-Meier survival curves during the pre-PET and PET periods for each disease stage. The 2-year survival rate for patients with stage III disease during the pre-PET period was 18% (95% CI, 16%-20%) compared with 22% (95% CI, 21%-24%) during the PET period. For patients with stage IV disease,

the 2-year survival rate in the pre-PET period was 6% (95% CI, 5%-7%), increasing to 8% in the PET period (95% CI, 7%-9%).

Adjusted Analysis

Cox proportional hazards regression analysis was performed to evaluate survival differences between PET periods and PET use, controlling for age, sex, race, disease stage, urban residence, and treatment received. **Table 3** provides estimates of adjusted HRs from the model. The PET period was found to be a significant predictor for better survival, with a reduced HR for death (0.95; 95% CI, 0.91-0.99) ($P = .02$). There was a significant difference in survival for patients with stage III and IV disease in the pre-PET period vs the PET period ($P < .001$) (Figure 2). In addition, PET use was significantly associated with a reduced HR for death in stage III (0.77; 95% CI, 0.69-0.85) and IV (0.64; 95% CI, 0.58-0.70) disease, but not for stage I and II disease. **Figure 3** and **Figure 4** provide Kaplan-Meier estimates for patients who underwent PET vs those who did not undergo PET for each disease stage during the combined pre-PET and PET periods as well as the PET period alone. Patients with stage III and IV disease who received PET had improved survival rates (Figures 3 and 4) ($P < .001$). Similar results were obtained for the pre-PET period alone (results not shown).

ADJUSTED SURVIVAL BASED ON PS

Propensity score matching is an alternative to the Cox multivariate adjustment for confounders. **Figure 5** shows Kaplan-Meier survival curves for disease stages I through IV based on PS-matched pairs (PET-yes and PET-no groups) for each stage. A significant improvement in survival was observed in the PET-yes group for disease stages III and IV ($P < .001$). For patients with stage III disease, receipt of surgical, chemotherapy, and radiation treatment was significantly different between the PET-yes and PET-no groups before PS matching. Furthermore, PS matching eliminated differences in receipt of surgical and radiation treatment. Survival differences because of PET use, stratified by chemotherapy treatment (using the PS-matched pairs), were also evaluated. Improved survival was again observed for patients who did not receive chemotherapy and were in the PET-yes group ($P < .001$), as well as in those who received chemotherapy ($P = .002$). For patients with stage IV disease, PS matching eliminated differences between surgical treatment and chemotherapy use, although there were some differences with respect to radiation use between the PET-yes and PET-no groups. Similarly, improved survival owing to PET use was observed among those who received radiation ($P < .001$) and those who did not ($P < .001$). Additional covariate/confounder adjustment was performed by including PS with covariates that could not be balanced (ie, chemotherapy use in stage III and radiation use in stage IV) in a survival analysis using the Cox regression model for each stage. As in the conventional multivariate modeling, results based on PS also indicate that PET use was strongly associated with a reduced risk of death among

Table 3. Clinical Variables Predictive of Survival: Cox Multivariate Regression Analysis^a

Clinical Variable	Hazard Ratio (95% CI)	P Value
Age at diagnosis	1.00 (1.00-1.01)	<.001
Male sex	1.21 (1.17-1.26)	<.001
Disease stage		
II	1.83 (1.61-2.09)	<.001
III	2.52 (2.33-2.72)	<.001
IV	3.80 (3.51-4.12)	<.001
Surgical treatment		
Lobectomy/partial pneumonectomy	0.29 (0.27-0.31)	<.001
Pneumonectomy	0.34 (0.29-0.39)	<.001
Lung procedure, not otherwise specified	0.41 (0.29-0.58)	<.001
Chemotherapy received	0.54 (0.52-0.56)	<.001
Radiation received	0.78 (0.74-0.81)	<.001
Post-PET period	0.95 (0.91-0.99)	.02
PET use by disease stage		
I	0.89 (0.78-1.02)	.10
II	0.82 (0.65-1.04)	.10
III	0.77 (0.69-0.85)	<.001
IV	0.64 (0.58-0.70)	<.001

Abbreviations: CI, confidence interval; PET, positron emission tomography.

^aCox model also included race and urban/rural residence; both were not found to be significant.

patients with stage III (HR, 0.72; 95% CI, 0.65-0.81) ($P < .001$) and IV (HR, 0.65; 95% CI, 0.59-0.71) ($P < .001$) disease, although not among patients with stage I (HR, 0.95; 95% CI, 0.83-1.09) ($P = .45$) and II (HR, 0.84; 95% CI, 0.66-1.07) ($P = .16$) disease. Furthermore, these HR estimates from the Cox regression models with PS added as a covariate for each stage are very similar to estimates based on the conventional Cox multivariate analysis using data from all stages.

COMMENT

Lung cancer will be diagnosed in more than 215 000 Americans in 2008 and remains the leading cause of cancer-related death among men and women.¹⁶ The most common subtype is NSCLC, which accounts for approximately 85% of all cases.¹⁷ Unfortunately, most patients are diagnosed as having locally advanced (stage III) or metastatic (stage IV) disease. In patients with stage IV NSCLC, treatment goals are palliative. Platinum-based chemotherapy, which modestly improves survival and quality of life in these patients, is often offered as the primary treatment.¹⁸

From 1994 to 2004, no significant improvement in survival was seen among patients with stage IV NSCLC following a series of large randomized controlled clinical trials.¹⁹⁻²¹ It was not until 2005 when a novel agent (bevacizumab) was found to improve survival outcomes when added to a platinum-based chemotherapy backbone.²² It is interesting to note that, from 1994 to 2004, clinical trials testing platinum-based combinations have reported numerical improvements in median survival time even though none of these trials showed superiority of either arm. For example, the median sur-




Figure 3. Kaplan-Meier survival curves by positron emission tomography (PET) use (PET-yes and PET-no groups) based on all data (1994-2004) for patients with stage I (A), stage II (B), stage III (C), and stage IV non-small cell lung cancer (D).

vival time of patients with NSCLC treated with the control regimen of carboplatin and paclitaxel in phase III trials ranged from 8 to 9 months in the mid- to late-1990s,^{17,23,24} later rising to 9.9 to 10.5 months in the early part of the 21st century.^{25,26} We wondered whether this change was in part owing to the Will Rogers' phenomenon, brought about by increased use of PET scanning.

In a population-based registry study of all NSCLC cases diagnosed in the Sacramento region, we found that the PET scan era (1999-2004) was strongly associated with improved survival compared with the pre-PET era (1994-1998). We also found that PET scan usage was an independent predictor of improved survival, even after adjustment for potentially confounding variables such as sex, age, and treatment received. It appears that many more patients are being diagnosed as having stage IV disease, with a concomitant decrease in the proportion of patients with stage III disease. It is likely that FDG-PET scan use has "up-staged" patients

who might otherwise be diagnosed as having stage III disease to stage IV by detecting distant metastatic disease not visualized by other routine imaging studies. It is not surprising that it is the stage III population that is most affected by stage migration (into stage IV) because of PET scans. After all, patients with stage III disease, who have bulkier primary tumors or mediastinal nodal involvement, have a much higher chance of occult distant metastases than those with stage I or II disease. These metastatic deposits are more readily detected by PET scans than by traditional imaging studies. It is also more likely that patients with stage III disease will have distant metastases that are larger than 10 mm in diameter, a threshold size that increases the likelihood of detection with PET scanning. In contrast, earlier stage tumors are more likely to harbor smaller, truly occult metastases below the limits of detection on PET scans. Nevertheless, stage migration could also have occurred in patients with stage I and II disease but may not have




Figure 4. Kaplan-Meier survival curves by positron emission tomography (PET) use (PET-yes and PET-no groups) based on 1999 to 2004 data for patients with stage I (A), stage II (B), stage III (C), and stage IV non-small cell lung cancer (D).

been detected by this analysis because of relatively small cohort sizes.

Limitations of our study include its regional nature (mitigated by its relative completeness), lack of detailed treatment information, and lack of prognostic information, such as weight loss and functional status. In addition, there is a bias as to which patients were selected to receive a PET scan. Patients who were not considered for further PET testing may have had a poor functional status or comorbidities, conditions that could have affected survival outcomes. The strengths of this analysis include its large sample size, representing all lung cancer cases diagnosed within the region from 1994 to 2004 and its ethnic diversity, enhancing its potential to be generalizable to the entire population. Our Cox model provides external validation for the data set since the clinical variables analyzed were consistent with known prognostic variables in NSCLC (eg, stage and treatment). Finally, our use of a stratified analysis as well as

matching based on PS further supported the results of the Cox multivariate model to account for potential confounders.

Our findings demonstrate that the Will Rogers phenomenon, originally described in relation to cancer staging in 1985, remains an important issue to consider when interpreting the results of clinical studies, particularly uncontrolled single-arm trials. Most important, this phenomenon is not limited to oncology and has been described in other biomedical fields. For example, more sensitive biomarkers of myocardial injury, such as troponin levels, may redefine patients with myocardial infarction and subsequently influence outcomes for this subset.²⁷ The phenomenon also has been described in the context of health care economics. Sicker patients were found to preferentially migrate from indemnity to managed care plans, resulting in apparent shifts in resource use.²⁸

In conclusion, our data support the hypothesis that enhanced survival for patients with stage III and IV NSCLC




Figure 5. Kaplan-Meier survival curves by positron emission tomography (PET) use (PET-yes vs PET-no groups; matched pairs) based on propensity score matching for patients with stage I (541 matched pairs) (A), stage II (134 matched pairs) (B), stage III (496 matched pairs) (C), and stage IV (549 matched pairs) (D) non-small cell lung cancer.

in the PET scan era is in part because of stage migration from III to IV. This migration is caused by the increased sensitivity of the PET scan and is not necessarily due solely to enhancements in oncological care.

Accepted for Publication: January 24, 2008.

Correspondence: Primo N. Lara Jr, MD, UC Davis Cancer Center, 4501 X St, Sacramento, CA 95817 (primo.lara@ucdmc.ucdavis.edu).

Author Contributions: Drs Chee, Wun, and Lara had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Chee, Wun, and Lara. *Acquisition of data:* Chee, Nguyen, and Brown. *Analysis and interpretation of data:* Nguyen, Brown, Gandara, Wun, and Lara. *Drafting of the manuscript:* Chee, Nguyen, Wun, and Lara. *Critical revision of the manuscript for important intellectual content:* Nguyen, Brown, Gandara, and Wun. *Sta-*

tistical analysis: Nguyen. *Obtained funding:* Lara. *Administrative, technical, and material support:* Chee, Brown, and Lara. *Study supervision:* Gandara, Wun, and Lara.

Financial Disclosure: None reported.

Funding/Support: This study was supported by grant UL1 RR024146 from the National Center for Research Resources. The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; contracts N01-PC-35136 (Northern California Cancer Center), N01-PC-35139 (University of Southern California), and N02-PC-15105 (Public Health Institute) from the Surveillance, Epidemiology and End Results Program, National Cancer Institute; and agreement U55/CCR921930-02 (Public Health Institute) from the National Program of Cancer Registries, Centers for Disease Control and Prevention.

Disclaimer: The ideas and opinions expressed herein are those of the authors. Endorsement by the National Center for Research Resources, the National Institutes of Health, the California Department of Health Services, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended and should not be inferred.

REFERENCES

1. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. *N Engl J Med.* 1985;312(25):1604-1608.
2. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. *N Engl J Med.* 2000;343(4):254-261.
3. Lee ST, Berlangieri SU, Poon AM, et al. Prevalence of occult metastatic disease in patients undergoing F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. *Intern Med J.* 2007;37(11):753-759.
4. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med.* 2006;354(5):496-507.
5. *Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals.* Sacramento: California Dept of Health Services, Cancer Surveillance Section; 2006. *California Cancer Reporting System Standards*; vol 1.
6. Percy CL, Van Holten V, Muir CS. *International Classification of Diseases for Oncology.* 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
7. Fritz A. *International Classification of Diseases for Oncology.* 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
8. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. *Cancer Causes Control.* 2001;12(8):703-711.
9. Greene FL; American Joint Committee on Cancer; American Cancer Society. *AJCC Cancer Staging Manual.* 6th ed. New York, NY: Springer-Verlag; 2002.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc.* 1958;53:457-481.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst.* 1959;22(4):719-774.
12. Cox DR. Regression models and life tables. *J Roy Statist Soc B.* 1972;34:187-202.
13. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. *Biometrika.* 1983;70:41-55.
14. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to non-randomized control group. *Stat Med.* 1998;17(19):2265-2281.
15. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the 26th Annual SAS Users Group International Conference. April 22-25, 2001; Long Beach, CA. Paper 214-26. <http://www2.sas.com/proceedings/sugi26/p214-26.pdf>. Accessed October 3, 2007.
16. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. *CA Cancer J Clin.* 2008;58(2):71-96.
17. Alberg AJ, Samet JM. Epidemiology of lung cancer. *Chest.* 2003;123(1)(suppl):21S-49S.
18. Spira A, Ettinger D. Multidisciplinary management of lung cancer. *N Engl J Med.* 2004;350(4):379-392.
19. Bunn PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? *J Clin Oncol.* 2002;20(18)(suppl):23S-33S.
20. Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. *Clin Cancer Res.* 2004;10(12 pt 2):4210s-4214s.
21. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med.* 2002;346(2):92-98.
22. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med.* 2006;355(24):2542-2550.
23. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. *J Clin Oncol.* 2001;19(13):3210-3218.
24. Williamson SK, Crowley J, Lara PN, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. *J Clin Oncol.* 2005;23(36):9097-9104.
25. Herbst RS, Giaccone G, Schiller J, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol.* 2004;22(5):785-794.
26. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol.* 2005;23(25):5892-5899.
27. Kontos MC, Fritz LM, Anderson FP, et al. Impact of the troponin standard on the prevalence of acute myocardial infarction. *Am Heart J.* 2003;146:446-452.
28. Young MJ, Lenhart J, Wasser T, et al. Evidence for the Will Rogers phenomenon in migration of employees to managed care plans. *J Gen Intern Med.* 1999;14(9):564-566.